Annual report
2413.TEDINET S100TVWH
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥238.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥169.2bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥131.0bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥64.4bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥72.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥68.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥58.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥34.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥45.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥37.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥21.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥48.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥52.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥490.8bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥400.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥346.0bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥273.1bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥221.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥124.1bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥91.1bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥366.7bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥309.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥264.0bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥351.9bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥302.6bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥257.8bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥199.8bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥166.1bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥149.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥104.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥89.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥47.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥58.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥46.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥26.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥39.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥3.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥49.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥11.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥43.4bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥66.68 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥55.73 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥31.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥66.63 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥55.68 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥31.88 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥516.49 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥444.22 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥293.64 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥244.24 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.2% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.9% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 13.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.5% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 20.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 12,100 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 10,533 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 9,384 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 8,249 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 7,127 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥51.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥54.5bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥49.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥23.6bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥26.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥84.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥28.0bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥30.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥84.5bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥27.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥75.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥19.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.2bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥251.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥232.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥215.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥195.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥163.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥25.2bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥70.6bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥226.0bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥162.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥152.5bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥139.8bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥122.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥105.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥87.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥111.85 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.14 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.41 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.03 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥111.77 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.12 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥32.38 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥18.02 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥21 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥331.17 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥237.22 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥205.3 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥180.54 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 39.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.8% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 679,063,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,964,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,785,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,645,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 649 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 588 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 574 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 554 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 473 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥3.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥3.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥863m |
| Career Solutionreportable segment | employees | at 2024-03-31 | 841 pure |
| Career Solutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥16.6bn |
| Career Solutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥16.6bn |
| Career Solutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥36m |
| Career Solutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| Evidence Solutionreportable segment | employees | at 2024-03-31 | 2366 pure |
| Evidence Solutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥26.7bn |
| Evidence Solutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Evidence Solutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥314m |
| Evidence Solutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| Medical Platformreportable segment | employees | at 2024-03-31 | 2321 pure |
| Medical Platformreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥93.4bn |
| Medical Platformreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥90.5bn |
| Medical Platformreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.9bn |
| Medical Platformreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥38.6bn |
| Overseasreportable segment | employees | at 2024-03-31 | 2657 pure |
| Overseasreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥69.9bn |
| Overseasreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥69.9bn |
| Overseasreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥16m |
| Overseasreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥11.7bn |
| Site Solutionreportable segment | employees | at 2024-03-31 | 3741 pure |
| Site Solutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Site Solutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Site Solutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥13m |
| Site Solutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥239.6bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥236.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥65.5bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥4.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥4.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥3.2bn |
| Career Solutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥14.5bn |
| Career Solutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥13.9bn |
| Career Solutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥669m |
| Career Solutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥4.6bn |
| Evidence Solutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥27.2bn |
| Evidence Solutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥26.5bn |
| Evidence Solutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥630m |
| Evidence Solutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥7.7bn |
| Medical Platformreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥93.1bn |
| Medical Platformreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥90.2bn |
| Medical Platformreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥2.9bn |
| Medical Platformreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥41.1bn |
| Overseasreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥62.1bn |
| Overseasreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥62.1bn |
| Overseasreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥25m |
| Overseasreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥17.0bn |
| Site Solutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥35.3bn |
| Site Solutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥35.0bn |
| Site Solutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥316m |
| Site Solutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥3.7bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥232.2bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥227.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥74.2bn |
| Medical Platformreportable segment | employees | at 2024-03-31 | 566 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,734
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 93414000000 | JPY |
| Revenue IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | 26700000000 | JPY |
| Revenue IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | 16642000000 | JPY |
| Revenue IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | 33025000000 | JPY |
| Revenue IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 69868000000 | JPY |
| Revenue IFRS | CurrentYearDuration_ReportableSegmentsMember | 239649000000 | JPY |
| Revenue IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | 2633000000 | JPY |
| Revenue IFRS | CurrentYearDuration_ReconcilingItemsMember | -3399000000 | JPY |
| Revenue IFRS | CurrentYearDuration | 238883000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 38626000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | 6698000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | 4781000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | 3735000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 11695000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_ReportableSegmentsMember | 65534000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | -290000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_ReconcilingItemsMember | -863000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 64381000000 | JPY |
| Finance income and expenses net IFRS | CurrentYearDuration | 4459000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 68840000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 255000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 1569000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_ReportableSegmentsMember | 1825000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | -468000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration | 1357000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 2747000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | 559000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | 194000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | 1806000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 3408000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_ReportableSegmentsMember | 8714000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | 163000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration | 8878000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 5531000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_ReportableSegmentsMember | 5531000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | 851000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | CurrentYearDuration | 6382000000 | JPY |
| Buildings and accompanying facilities IFRS | Prior1YearInstant | 5852000000 | JPY |
| Furniture and fixtures IFRS | Prior1YearInstant | 1028000000 | JPY |
| Right of use assets IFRS | Prior1YearInstant | 9469000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |